|
1.
|
Shaaban A and Rezvani M: Ovarian cancer:
detection and radiologic staging. Clin Obstet Gynecol. 52:73–93.
2009. View Article : Google Scholar
|
|
2.
|
Chen WQ, Zhang SW and Zou XN: Cancer
incidence and mortality in China, 2006. Chin J Cancer Res. 23:3–9.
2011.(In Chinese).
|
|
3.
|
Nolen BM and Lokshin AE: Protein
biomarkers of ovarian cancer: the forest and the trees. Future
Oncol. 8:55–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Li J, Dowdy S, Tipton T, et al: HE4 as a
biomarker for ovarian and endometrial cancer management. Expert Rev
Mol Diagn. 9:555–566. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Kirchhoff C, Habben I, Ivell R and Krull
N: A major human epididymis-specific cDNA encodes a protein with
sequence homology to extracellular proteinase inhibitors. Biol
Reprod. 45:350–357. 1991. View Article : Google Scholar
|
|
6.
|
Kirchhoff C: Molecular characterization of
epididymal proteins. Rev Reprod. 3:86–95. 1998. View Article : Google Scholar
|
|
7.
|
Galgano MT, Hampton GM and Frierson HF Jr:
Comprehensive analysis of HE4 expression in normal and malignant
human tissues. Mod Pathol. 19:847–853. 2006.PubMed/NCBI
|
|
8.
|
Moore RG, Brown AK, Miller MC, Skates S,
Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P,
Granai CO and Bast RC Jr: The use of multiple novel tumor
biomarkers for the detection of ovarian carcinoma in patients with
a pelvic mass. Gynecol Oncol. 108:402–408. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Köbel M, Kalloger SE, Boyd N, McKinney S,
Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice
LM, Miller D, Santos J, Swenerton K, Gilks CB and Huntsman D:
Ovarian carcinoma subtypes are different diseases: implications for
biomarker studies. PLoS Med. 5:e2322008.PubMed/NCBI
|
|
10.
|
Deraco M, Baratti D, Laterza B, et al:
Advanced cytoreduction as surgical standard of care and
hyperthermic intraperitoneal chemotherapy as promising treatment in
epithelial ovarian cancer. Eur J Surg Oncol. 37:4–9. 2011.
View Article : Google Scholar
|
|
11.
|
Chua TC, Liauw W, Robertson G and Morris
DL: Second-line treatment of first relapse recurrent ovarian
cancer. Aust N Z J Obstet Gynaecol. 50:465–471. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Berry NB, Cho YM, Harrington MA, Williams
SD, Foley J and Nephew KP: Transcriptional targeting in ovarian
cancer cells using the human epididymis protein 4 promoter. Gynecol
Oncol. 92:896–904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Moore RG, McMeekin DS, Brown AK,
DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC
Jr and Skates SJ: A noval multiple marker bioassay utiliazing HE4
and CA125 for the prediction of ovarian cancer in patients with a
pelvic mass. Gynecol Oncol. 112:40–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Wang K, Gan L, Jeffery E, Gayle M, Gown
AM, Skelly M, Nelson PS, Ng WV, Schummer M, Hood L and Mulligan J:
Monitoring gene expression profile changes in ovarian carcinomas
using cDNA microarray. Gene. 229:101–108. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Drapkin R, von Horsten HH, Lin Y, Mok SC,
Crum CP, Welch WR and Hecht JL: Human epididymis protein 4 (HE4) is
a secreted glycoprotein that is overexpressed by serous
andendometrioid ovarian carcinomas. Cancer Res. 65:2162–2169. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Montagnana M, Lippi G, Ruzzenente O,
Bresciani V, Danese E, Scevarolli S, Salvagno GL, Giudici S,
Franchi M and Guidi GC: The utility of serum human epididymis
protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal.
23:331–335. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Nolen B, Velikokhatnaya L, Marrangoni A,
De Geest K, Lomakin A, Bast RC Jr and Lokshin A: Serum biomarker
panels for the discrimination of benign from malignant cases in
patients with an adnexal mass. Gynecol Oncol. 117:440–445. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Andersen MR, Goff BA, Lowe KA, Scholler N,
Bergan L, Drescher CW, Paley P and Urban N: Use of a symptom index,
CA125, and HE4 to predict ovarian cancer. Gynecol Oncol.
116:378–383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Xu CL, Yang YH and Wang HL: The value of
serum human epididymis protein 4 epithelial in the diagnosis of
ovarian cancer. Chinese Journal of Gynecology and Obstetrics.
26:684–686. 2010.
|
